Singular Genomics Systems Stock Probability of Future Stock Price Finishing Over 22.53
| OMIC Stock | USD 20.16 0.16 0.80% |
Singular |
Singular Genomics Target Price Odds to finish over 22.53
The tendency of Singular Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 22.53 or more in 90 days |
| 20.16 | 90 days | 22.53 | about 11.21 |
Based on a normal probability distribution, the odds of Singular Genomics to move over $ 22.53 or more in 90 days from now is about 11.21 (This Singular Genomics Systems probability density function shows the probability of Singular Stock to fall within a particular range of prices over 90 days) . Probability of Singular Genomics Systems price to stay between its current price of $ 20.16 and $ 22.53 at the end of the 90-day period is about 13.16 .
Given the investment horizon of 90 days Singular Genomics has a beta of 0.0303. This indicates as returns on the market go up, Singular Genomics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Singular Genomics Systems will be expected to be much smaller as well. In addition to that Singular Genomics Systems has an alpha of 2.7586, implying that it can generate a 2.76 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Singular Genomics Price Density |
| Price |
Predictive Modules for Singular Genomics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Singular Genomics Systems. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Singular Genomics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Singular Genomics is not an exception. The market had few large corrections towards the Singular Genomics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Singular Genomics Systems, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Singular Genomics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 2.76 | |
β | Beta against Dow Jones | 0.03 | |
σ | Overall volatility | 4.55 | |
Ir | Information ratio | 0.15 |
Singular Genomics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Singular Genomics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Singular Genomics Systems can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Singular Genomics is way too risky over 90 days horizon | |
| Singular Genomics appears to be risky and price may revert if volatility continues | |
| Singular Genomics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 2.91 M. Net Loss for the year was (94.82 M) with loss before overhead, payroll, taxes, and interest of (24 K). | |
| Singular Genomics Systems currently holds about 287.98 M in cash with (73.65 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.05. | |
| Singular Genomics has a poor financial position based on the latest SEC disclosures | |
| Roughly 60.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 250 shares by Eli Glezer of Singular Genomics subject to Rule 16b-3 |
Singular Genomics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Singular Stock often depends not only on the future outlook of the current and potential Singular Genomics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Singular Genomics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 2.4 M | |
| Cash And Short Term Investments | 173.9 M |
Singular Genomics Technical Analysis
Singular Genomics' future price can be derived by breaking down and analyzing its technical indicators over time. Singular Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Singular Genomics Systems. In general, you should focus on analyzing Singular Stock price patterns and their correlations with different microeconomic environments and drivers.
Singular Genomics Predictive Forecast Models
Singular Genomics' time-series forecasting models is one of many Singular Genomics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Singular Genomics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Singular Genomics Systems
Checking the ongoing alerts about Singular Genomics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Singular Genomics Systems help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Singular Genomics is way too risky over 90 days horizon | |
| Singular Genomics appears to be risky and price may revert if volatility continues | |
| Singular Genomics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 2.91 M. Net Loss for the year was (94.82 M) with loss before overhead, payroll, taxes, and interest of (24 K). | |
| Singular Genomics Systems currently holds about 287.98 M in cash with (73.65 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.05. | |
| Singular Genomics has a poor financial position based on the latest SEC disclosures | |
| Roughly 60.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 250 shares by Eli Glezer of Singular Genomics subject to Rule 16b-3 |
Check out Singular Genomics Backtesting, Singular Genomics Valuation, Singular Genomics Correlation, Singular Genomics Hype Analysis, Singular Genomics Volatility, Singular Genomics History as well as Singular Genomics Performance. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Singular Genomics. If investors know Singular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Singular Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (34.68) | Revenue Per Share 1.107 | Quarterly Revenue Growth 0.459 | Return On Assets (0.24) | Return On Equity (0.52) |
The market value of Singular Genomics Systems is measured differently than its book value, which is the value of Singular that is recorded on the company's balance sheet. Investors also form their own opinion of Singular Genomics' value that differs from its market value or its book value, called intrinsic value, which is Singular Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Singular Genomics' market value can be influenced by many factors that don't directly affect Singular Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Singular Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Singular Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Singular Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.